N-[芴甲氧羰基]-O-苄基-D-苏氨酸 | 131545-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N-[芴甲氧羰基]-O-苄基-D-苏氨酸
• 英文名称: Fmoc-D-Thr(OBzl)-OH
• 英文别名: Fmoc-O-benzyl-D-threonine；Fmoc-D-Thr(Bn)-OH；Fmoc-D-Thr(Bzl)-OH；(2R,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(benzyloxy)butanoic acid；(2R,3S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenylmethoxybutanoic acid
• CAS: 131545-63-6
• 化学式: C₂₆H₂₅NO₅
• 分子量: 431.488
• InChiKey: UCDMMWCWPVCHLL-BXKMTCNYSA-N

物化性质

• 沸点：
  643.7±55.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  N-[芴甲氧羰基]-O-苄基-D-苏氨酸 在 4-二甲氨基吡啶 、 N-羟基-5-降冰片烯-2,3-二甲酰亚胺 、 二乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 59.0h， 生成 N-(3-BzlO-4-Me-2-nitrobenzoyl)-O-(Boc-MeVal)Thr-D-Thr-(OBzl)-Pro-Sar-OtBu
  参考文献：
  名称：

  放线菌素D的某些肽类似物的合成和性质。

  摘要：

  合成了放线菌素D（AMD）的类似物，其中在肽部分的不同位点进行了氨基酸置换。这些包括（i）用N-甲基亮氨酸替换两个N-甲基缬氨酸，（ii）用N- [2-（甲氧基羰基乙基）甘氨酸替换两个肌氨酸，和（iii）用D替换一个或两个D-缬氨酸。 -苏氨酸。替代ii和iii的目的是确定引入新的侧链对生物学活性的影响，该侧链可以进行功能化以允许连接载体分子（例如抗体）。NMR数据表明没有类似物具有与AMD显着不同的溶液构象。与DNA的差异光谱表明，置换i增强了结合，而其他类似物与DNA的结合则不那么牢固。所有类似物的抗菌活性均低于AMD。相反，5,5'-（MeLeu）2AMD在低约100倍的浓度下显示出与AMD相当的体外抗肿瘤活性。

  DOI：

  10.1021/jm00108a009

文献信息

• Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples
  作者：Wioletta Rut、Marcin Poręba、Paulina Kasperkiewicz、Scott J. Snipas、Marcin Drąg

  DOI：10.1021/acs.jmedchem.8b00026

  日期：2018.6.28

  the HyCoSuL approach, we designed and synthesized novel and selective fluorogenic substrates for each of these three constitutive 20S proteasome activities and applied them to assess inhibition of proteasome subunits by MG-132 and a clinically used inhibitor bortezomib. Our results confirm the utility of designed substrates in biochemical assays. Furthermore, selective peptide sequences obtained in this

  蛋白酶体是维持蛋白质稳态的关键酶复合物。蛋白酶体功能紊乱导致包括癌症，自身免疫和神经退行性疾病在内的病理。因此，蛋白酶体构成药物开发的极好的分子靶标。在这里，我们使用HyCoSuL方法为这三个20S组成型蛋白酶体活性中的每一个设计和合成了新颖的选择性荧光底物，并将它们应用于评估MG-132和临床使用的硼替佐米对蛋白酶体亚基的抑制作用。我们的结果证实了设计的底物在生化分析中的实用性。此外，以此方式获得的选择性肽序列用于构建荧光团标记的基于活性的探针，然后用于同时检测HEK-293F细胞和红细胞裂解液中的每个20S组成型蛋白酶体亚基。总体而言，我们描述了一种简单而快速的方法，可用于测量全血样本中20S组成型蛋白酶体的活性，该方法可以早期诊断与异常上调的蛋白酶体活性有关的病理状态。
• Linker Variation and Structure–Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors
  作者：Francisco Lopez-Tapia、Christine Brotherton-Pleiss、Peibin Yue、Heide Murakami、Ana Carolina Costa Araujo、Bruna Reis dos Santos、Erin Ichinotsubo、Anna Rabkin、Raj Shah、Megan Lantz、Suzie Chen、Marcus A. Tius、James Turkson

  DOI：10.1021/acsmedchemlett.7b00544

  日期：2018.3.8

  investigated to design optimized analogues. All three leads are based on an N-methylglycinamide scaffold, with its two amine groups condensed with three different functionalities. The three functionalities and the CH2 group of the glycinamide scaffold were separately modified. The replacement of the pentafluorobenzene or cyclohexylbenzene, or replacing the benzene ring of the aromatic carboxylic or hydroxamic

  研究了已报道的苯甲酸（SH4-54），水杨酸（BP-1-102）和苯并异羟肟酸（SH5-07）的STAT3抑制剂的分子决定因素，以设计优化的类似物。所有三个导联均基于N-甲基甘氨酰胺支架，其两个胺基缩合成三个不同的官能团。甘氨酰胺支架的三个功能和CH 2基团分别进行了修饰。五氟苯或环己基苯的取代，或用杂环成分（含氮和氧元素）取代芳族羧酸或异羟肟酸基序的苯环，均会降低效能。值得注意的是，Ala-linker类似物1a和2v，以及在手性中心均具有（R）构型的基于Pro的衍生物5d在体外具有更高的抑制活性和针对STAT3 DNA结合活性的选择性，IC 50为3.0±0.9、1.80±0.94和2.4分别为±0.2μM。化合物1a，2v，5d和其他类似物在人乳腺癌和黑色素瘤细胞系中抑制STAT3组成型STAT3的磷酸化和激活，并在体外阻断肿瘤细胞的活力，生长，集落形成和迁移。基于专业的模拟，5h具
• Protein–Protein Interface Mimicry by an Oxazoline Piperidine-2,4-dione
  作者：Xun Li、Jaru Taechalertpaisarn、Dongyue Xin、Kevin Burgess

  DOI：10.1021/ol5036547

  日期：2015.2.6

  Representative minimalist mimics 1 were prepared from amino acids. Scaffold 1 was not designed to mimic any particular secondary structure, but simulated accessible conformations of this material were compared with common ideal secondary structures and with >125,000 different protein-protein interaction (PPI) interfaces. This data mining exercise indicates that scaffolds 1 can mimic features of sheet-turn-sheets, somewhat fewer helical motifs, and numerous PPI interface regions that do not resemble any particular secondary structure.
• [EN] INHIBITORS OF STAT3 AND USES THEREOF<br/>[FR] INHIBITEURS DU STAT3 ET LEURS UTILISATIONS
  申请人：UNIV TEXAS

  公开号：WO2010118309A3

  公开（公告）日：2011-01-13
• Structure−Affinity Relationships of Glutamine Mimics Incorporated into Phosphopeptides Targeted to the SH2 Domain of Signal Transducer and Activator of Transcription 3
  作者：Pijus K. Mandal、Zhiyong Ren、Xiaomin Chen、Chiyi Xiong、John S. McMurray

  DOI：10.1021/jm901105k

  日期：2009.10.8

  In cancer cells, signal transducer and activator of transcription 3 (Stat3) participates in aberrant growth, survival, angiogenesis, and invasion signals and is a validated target for anticancer drug design. We are targeting its SH2 domain to prevent docking to cytokine and growth factor receptors and subsequent signaling. One of the important elements of the recognition sequence, pTyr-Xxx-Xxx-Gln, is glutamine. We incorporated novel Gin mimics into a lead peptide, pCinn-Leu-Pro-Gln-NHBn, and found that a linear, unconstrained side chain and carboxamide are necessary for high affinity, and the benzamide can be eliminated. Replacement of Gln-NHBn with (R)-4-aminopentanamide or 2-aminoethylurea produced inhibitors with equal or greater potency than that of the lead, as judged by fluorescence polarization (IC50 values were 110 and 130 nM, respectively). When Pro was replaced with cis-3,4-methanoproline, the glutamine mimic, (4R,5S)-4-amino-5-benzyloxyhexanamide resulted in an IC50 of 69 nM, the highest affinity Stat3 inhibitor reported to date.